Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/HJR.0b013e3283386462 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Elevated Lipoprotein(a) Levels and Massive Ruptured Root and Ascending Aortic Aneurysm.
JACC Case Rep
September 2025
Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada; Division of Cardiac Surgery, St Michael's Hospital of Unity Health Toronto, Li Ka Shing Knowledge Institute, Toronto, Ontario, Canada; Department of Surgery, University of Toronto, Toronto, Ontario, Canada; Department of P
Background: Rupture of a root and ascending aortic aneurysm is a rare, life-threatening condition requiring prompt recognition and surgical intervention. Elevated lipoprotein(a) levels have been implicated in vascular pathology but are less studied in thoracic aneurysms.
Case Summary: A 61-year-old man who presented with severe dyspnea and chest tightness was found to have a 7.
Minimally Important Kansas City Cardiomyopathy Questionnaire Changes Across the Spectrum of Heart Failure Severity.
JACC Heart Fail
September 2025
University of Missouri Healthcare Institute for Innovations in Quality, Kansas City, Missouri, USA; Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
Background: Although the Kansas City Cardiomyopathy Questionnaire (KCCQ) assesses important outcomes for patients with heart failure, whether a 5-point change in KCCQ represents a minimal clinically important difference (MCID) in an individual patient with very poor, as compared with very good, heart failure severity is unknown.
Objectives: This study aims to define MCIDs for the KCCQ-Overall Summary Score (OSS) and KCCQ-Clinical Summary Score (CSS) across the range of baseline health status.
Methods: Outpatients with heart failure with ejection fractions ≤40% recruited from 14 clinics completed KCCQs at baseline and 6 ± 2 weeks later, along with a 15-point Likert scale assessing their perceived changes in health status.
Generalizability of SURPASS-CVOT to the United States: A Nationally Representative Study.
Prog Cardiovasc Dis
September 2025
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address:
Effect of evolocumab on saphenous vein graft patency after coronary artery bypass surgery (NEWTON-CABG CardioLink-5): an international, randomised, double-blind, placebo-controlled trial.
Lancet
August 2025
Department of Anesthesia, St Michael's Hospital-Unity Health Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada; Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, ON, Canada; Department of Physiology, Univ
Background: Saphenous vein graft (SVG) failure remains a substantial challenge after coronary artery bypass graft (CABG). LDL cholesterol (LDL-C) is a causal risk factor for atherosclerosis, but its role in SVG failure is not well established. We evaluated whether early initiation of intensive LDL-C lowering with evolocumab could reduce SVG failure.
View Article and Find Full Text PDFPathogenic Cardiomyopathy-Associated Gene Variants and Prognosis in Atrial Fibrillation: Results in 18,000 Clinical Trial Participants.
J Am Coll Cardiol
September 2025
Thrombolysis in Myocardial Infarction Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA; Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Electronic address:
Background: Genetic variants in cardiomyopathy genes are associated with risk of atrial fibrillation (AF), although data on clinical outcomes for AF patients with such variants remain sparse.
Objectives: We aimed to study the prognostic implication of rare cardiomyopathy-associated pathogenic variants (CMP-PLP) in AF patients from large, well-phenotyped clinical trials.
Methods: CMP-PLP carriers were identified using exome sequencing in 5 multinational trials from the Thrombolysis in Myocardial Infarction study group (ENGAGE AF, FOURIER, SAVOR, PEGASUS, and DECLARE), with replication in the EAST-AFNET-4 trial.